Psychiatry cant be ignored - here’s why 👉Many medications that make a meaningful difference in ME/CFS, POTS and Long Covid are often classified as “psychiatric medications”. 🚨
The clinical question is not whether a medication is psychiatric, neurological, immunological or cardiovascular. The question is whether it targets a relevant biological process.
Psychopharmacology provides a major framework for targeting several domains seen in ME/CFS, POTS and Long Covid: autonomic instability, hyperarousal, sleep disruption, pain amplification, cognitive dysfunction, sensory sensitivity, fatigue, threat circuitry, inflammatory signalling and mast-cell-related pathways.
But psychiatry is portrayed as the emery. Most patients are seen by psychiatry late in the picture and it’s often when physicians have tried everything and now they refer to psychiatry .
So the irony is psychiatry is really a refuge for the physician’s hopelessness here .
So the list - not exhaustive, but includes
1. Naltrexone / low-dose naltrexone
2. Aripiprazole / low-dose aripiprazole
3. Memantine
4. Prazosin and clonidine
5.Guanfacine
6. Vortioxetine
7. Psychostimulants - methylphenidate, dexamphetamine, lisdexamfetamine
8. Modafinil and armodafinil
9. SNRIs :duloxetine, venlafaxine, desvenlafaxine, milnacipran
11. TCAs : amitriptyline, nortriptyline, doxepin
12. Mirtazapine, Trazodone
13. Gabapentinoids : pregabalin, gabapentin
14.Beta-blockers : propranolol
15.’Benzodiazepines
16.Melatonin
17.Low-dose antipsychotics with antihistaminergic properties where hyperarousal, sensory amplification or agitation are dominant
18. Mood stabilisers / anti-kindling agents -e.g lamotrigine in highly selected neuropsychiatric phenotypes
Many of these medications are called psychiatric because psychiatrists are often the clinicians most familiar with their mechanisms, dosing, adverse effects, interactions and clinical sequencing.
Most physician’s struggle to use these appropriately because this is psychopharmacology.
That does not mean they are only treating depression or anxiety.
And if the construct infront of them is anxiety or ADHD or agitated depression then the medications re used in a very specific way that makes a difference
Several agents used in psychopharmacology have effects on inflammatory signalling, autonomic tone, sleep architecture, pain processing, cognition, arousal, mast-cell-related symptoms, or central threat prediction.
This is where the mind–body split becomes clinically unhelpful.
A patient may decline an “antidepressant” because they do not have depression.
A clinician may avoid a medication because it is seen as psychiatric.
A biological target may then be missed because the medication carries the wrong label.
In practice, when brain–body integration is understood, the framing changes.
These medications are biological tools.
And in complex conditions such as ME/CFS, POTS and Long Covid, dismissing them because of category stigma can limit treatment options and reinforce the very split that prevents more integrated care.
A recent review proposes integrating POTS, ME/CFS, and Long COVID into the neuroimmunology subspecialty. Here is their compelling case.
\ Overlapping Drivers of Disease:
The authors outline several major overlapping pathophysiological mechanisms shared by POTS, ME/CFS, and Long COVID. This includes:
1. Autonomic Dysfunction (Dysautonomia)
2. Mitochondrial Dysfunction
3. Cerebral Hypoperfusion
4. Immune Dysregulation
5. Neuroinflammation
6. Autoimmunity
\ The Harm of Psychiatric Misdiagnoses:
For decades, patients have been wrongly labeled with "functional neurological disorder," anxiety, or somatization because routine tests often look normal.
\ A Call for Better Diagnostics:
Researchers and clinicians urgently need advanced tools such as:
- 7T MRIs
- Targeted PET scans
- Autoantibody and cytokine panels
- Comprehensive autonomic function testing
Routine tests are simply not enough.
\ The Authors’ Core Proposal:
Classify and treat POTS, ME/CFS, and Long COVID as neuroimmune disorders under the subspecialty of neuroimmunology.
This shift would:
• Improve clinical care
• Accelerate research
• Enable effective neurotherapeutics (including repurposed immunomodulatory and anti-inflammatory treatments)
Thanks, Dysautonomia Clinic, for the awesome paper!
#MECFS #POTS #LONGCOVID #PASC
Read more here:
buff.ly/HqR7NKH